<i id='AAEC6D07AF'><strike id='AAEC6D07AF'><tt id='AAEC6D07AF'><pre id='AAEC6D07AF'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
How one medical school became remarkably diverse 
Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say 
Alkermes shareholders re 
UpToDate has a racism problem: Dr. Stanley Goldfarb
Alkermes shareholders re 
Use doctors trained outside the U.S. to ease the physician shortage 
Hollywood unions extend contract negotiations for actors 
NYC plans to house migrants on an island in the East River 
New air purifier tech could be key to improving indoor air quality 
Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images 
Moonlake's readout produced a cash windfall. Risks remain 
Penis shrinkage, a side effect of prostate cancer surgery, is temporary 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
Drug cartel violence flares in western Mexico after vigilante leader's killing 
The cancer drug shortage isn’t new — and neither are the solutions 
